THE ARISING · Longevity & Healthspan
Isomorphic Labs raises $5 billion for AI drug design
The financing will help Demis Hassabis’s company move drug candidates toward trials in people. It does not tell us whether those drugs will work.
Isomorphic Labs announced a $5 billion Series C financing on November 17. Greenoaks and Sequoia Capital co-led the round, with participation from Alphabet, Andreessen Horowitz and other investors. The London-based company announced a separate $2.1 billion Series B in May, bringing its disclosed financing from these two rounds to $7.1 billion this year.
The company plans to use the money to expand its AI drug-design platform, grow its internal and partnered pipelines, and build the infrastructure needed to move candidates into clinical studies. It reports encouraging preclinical results from its own oncology and immunology programs and from work with partners. The announcement does not contain human trial results.
There are two different kinds of progress here. A model can help researchers decide what to test next. That matters when many plausible designs would be slow and expensive to explore in the lab. But a candidate that looks promising in a model or a preclinical study can still fail in people. Clinical trials have to establish what dose patients can tolerate, whether the drug helps, and whether its benefits outweigh its harms.
The next milestone to watch is not a larger round or a better benchmark. It is a registered human study of an Isomorphic candidate, followed by results showing how the drug actually performs. This is a major investment in a platform for developing medicines across several diseases, not $5 billion earmarked for aging biology or proof that the platform extends healthy life.